Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Our findings suggest that combinatorial inhibition of CK2 and KIT warrants evaluation as a novel therapeutic strategy in GIST, especially in imatinib-resistant GIST. 31776458 2020
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE This case illustrates that knowing the specific type of KIT mutations may uncover resistance of certain GIST's to TKIs, necessitating more targeted and alternative therapy. 31702819 2020
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Additional genetic events including RB1, SMARCB1, and MAX except secondary KIT/PDGFRA mutations are the most common for GISTs to evolve into resistant disease. 31758409 2020
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Gastrointestinal stromal tumors (GISTs) are one of the most common mesenchymal tumor types and usually contain KIT or PDGFRA mutations. 31570771 2020
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE WEE1 inhibition could promote KIT autophagic degradation and, therefore, targeting WEE1 might represent a novel strategy for GIST therapies. 31197522 2020
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different <i>KIT</i> mutations, with differential sensitivity to standard TKI.<b>Experimental Design:</b> NMRI <i>nu/nu</i> mice (<i>n</i> = 93) were transplanted with human GIST xenografts with <i>KIT</i> exon 11+17 (UZLX-GIST9 <i> 30274985 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) constitute a small KIT/PDGFRA-WT GIST subgroup featuring DNA methylation which, although pervasive, appears nevertheless not randomly distributed. 30616628 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs. 31085175 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Around 90% of GISTs contain mutations in KIT or PDGFRA and the remaining 10% of GISTs are wild-type. 30003531 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 AlteredExpression group BEFREE CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour. 31552107 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Patients with KIT exon 11 mutations had better PFS compared to those with KIT exon 9 mutations or wild-type GISTs (p = .017, p = .040, respectively). 30346846 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors. 31076599 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Furthermore, DEPDC5 modulates the sensitivity of GIST to KIT inhibitors, and the combination therapy with mTOR inhibitor and KIT inhibitor may work better in GIST patients with DEPDC5 inactivation. 31636198 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE Approximately 15% of adult patients with GISTs are negative for mutations in KIT or PDGFRA genes. 31708372 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE The IHC characteristic of GIST in descending order showed positivity for vimentin (88.9%), CD117 (83.3%), CD34 (77.8%), Ki67 (63.9%), SMA (38.9%), desmin (27.8%), and S100 (19.4%). 30723856 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Succinate dehydrogenase (SDH)-deficient GISTs are wild type and lack KIT proto-oncogene receptor tyrosine kinase and platelet-derived growth factor receptor A ( KIT or PDGFRA) mutations. 30301441 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE We performed RNA sequencing of 75 human GIST tumors from 75 patients, comprising the largest cohort of GISTs sequenced to date, in order to discover differences in the immune infiltrates of KIT and PDGFRA-mutant GIST. 30762585 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Combinations with KIT or MEK inhibitors completely abrogated GIST-survival signaling and displayed synergistic effects. 31308077 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 AlteredExpression group BEFREE Dual inhibition of KIT and MAPK pathways has synergistic antitumor activity in preclinical GIST models. 31213500 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Dedifferentiation in GIST is a rare histologic change which may occur de novo or secondary to imatinib therapy and is characterized by abrupt transition of well-differentiated (WD) GIST to a subclonal anaplastic process that shows loss of immunohistochemical marks (CD117, DOG1). 31072206 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE The prognosis and the clinical course of these tumors is different from that of KIT- or PDGFR-α-mutated GISTs. 31169996 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE The pathological findings were compatible with GIST and the tumor consisted of spindle cells with positive staining for KIT, CD34, and DOG1 and negative or weak staining for desmin and S-100 protein. 30943904 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. 31250638 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 Biomarker group BEFREE Taken together, these results demonstrate the existence of a nuclear KIT-driven NFKBIB-RELA-KIT autoregulatory loop in GIST tumorigenesis, which are potential targets for developing combination therapy to overcome imatinib-resistant of KIT-expressing GISTs. 31363162 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
1.000 GeneticVariation group BEFREE In particular, a discovery cohort (34 GIST with a KIT exon 11 primary mutation, and no toxicity) was analyzed through DMET array that interrogates 1936 variants in 231 genes of the ADME process. 30237583 2019